Force, J., Holl, E., Brown, M., Marcom, P. K., Grimm, L., Boczkowski, D., … Nair, S. (2018). Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy. In Journal of Clinical Oncology (Vol. 36, pp. e12641–e12641). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.e12641

Force, Jeremy, Eda Holl, Michael Brown, Paul Kelly Marcom, Lars Grimm, David Boczkowski, Victoria Frazier, et al. “Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.” In Journal of Clinical Oncology, 36:e12641–e12641. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e12641.

Force J, Holl E, Brown M, Marcom PK, Grimm L, Boczkowski D, et al. Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e12641–e12641.

Force, Jeremy, et al. “Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. e12641–e12641. Crossref, doi:10.1200/jco.2018.36.15_suppl.e12641.

Force J, Holl E, Brown M, Marcom PK, Grimm L, Boczkowski D, Frazier V, Herndon JE, Bigner DD, Hwang E-SS, Gromeier M, Nair S. Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e12641–e12641.